FULCRUM THERAPEUTICS INC (FULC) Earnings History & Surprises

NASDAQ:FULCUS3596161097

Current stock price

7.44 USD
-0.21 (-2.75%)
At close:
7.44 USD
0 (0%)
After Hours:

FULC Earnings overview

Past quarterly earnings results for FULCRUM THERAPEUTICS INC (FULC), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).

Earnings Snapshot

Next Earnings Date

Upcoming
Release Date
Apr 29, 2026
Period
Q1 / 2026
EPS Estimate
-$0.30
Revenue Estimate

Last Reported

Most Recent
Release Date
Feb 24, 2026
Period
Q4 / 2025
EPS Reported
-$0.31
EPS Surprise
1.67%
Revenue Surprise
%

Beat Rate

Last 8 Quarters
44%
EPS and Revenue beats vs estimates

Quarterly Earnings Historical Results

EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.

QuarterEPSEPS EstEPS SurpriseEPS Q2QRevenueRevenue EstRevenue SurpriseRevenue Q2Q
Q4 2025 -0.31 -0.32 1.67% - - -
Q3 2025 -0.31 -0.30 -3.46% 11.43% - -
Q2 2025 -0.28 -0.30 5.34% -132.18% - -100.00%
Q1 2025 -0.28 -0.30 6.63% 34.88% - -
Q4 2024 -0.31 -0.33 5.45% 22.50% - -100.00%
Q3 2024 -0.35 -0.41 15.39% 10.26% - -100.00%
Q2 2024 0.87 -0.01 6,923.53% 328.95% 80M 37.276M 114.62% 8,990.91%
Q1 2024 -0.43 -0.45 3.64% -4.88% 367.343K -100.00% -100.00%
Q4 2023 -0.40 -0.43 7.88% 20.00% 871K 470.393K 85.16% 26.23%
Q3 2023 -0.39 -0.44 12.10% 23.53% 759K 1.073M -29.26% -35.68%
Q2 2023 -0.38 -0.45 16.20% 54.22% 880K 1.138M -22.67% -53.19%
Q1 2023 -0.41 -0.46 11.75% 35.94% 295K 1.15M -74.35% -88.61%
Q4 2022 -0.50 -0.50 -0.06% 13.79% 690K 1.687M -59.10% -86.36%
Q3 2022 -0.51 -0.62 18.32% 10.53% 1.18M 2.594M -54.51% -76.11%
Q2 2022 -0.83 -0.67 -23.17% -38.33% 1.88M 3.024M -37.83% -57.08%
Q1 2022 -0.64 -0.64 -0.11% -18.52% 2.59M 4.023M -35.62% -45.93%
Q4 2021 -0.58 -0.74 21.83% 9.38% 5.06M 2.733M 85.14% 19.62%
Q3 2021 -0.57 -0.66 13.59% 18.57% 4.94M 2.295M 115.25% 167.03%
Q2 2021 -0.60 -0.64 5.81% 9.09% 4.38M 1.629M 168.88% 119.00%
Q1 2021 -0.54 -0.67 19.42% 33.33% 4.79M 1.454M 229.44% 538.67%
Q4 2020 -0.64 -0.74 13.46% - 4.23M 1.332M 217.57% -
Q3 2020 -0.70 -0.67 -5.04% - 1.85M 561K 229.77% -
Q2 2020 -0.66 -0.79 16.62% - 2M - -
Q1 2020 -0.81 -0.77 -5.41% - 750K - -

Notes

  • EPS and Revenue values are non-GAAP when available, otherwise GAAP.
  • Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
  • Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
  • Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.

Earnings Q2Q Performance Trends

EPS Historical Q2Q growth and Acceleration

FULC EPS Q2Q GrowthFULC EPS Q2Q GrowthEPS Q2Q Growth Q1/21 Q3/21 Q1/22 Q3/22 Q1/23 Q3/23 Q1/24 Q3/24 Q1/25 Q3/25 Q1/26 Q3/26 0 100 -100 200 300

Revenue Historical Q2Q growth and Acceleration

FULC Revenue Q2Q GrowthFULC Revenue Q2Q GrowthRevenue Q2Q Growth Q1/21 Q2/21 Q3/21 Q4/21 Q1/22 Q2/22 Q3/22 Q4/22 Q1/23 Q2/23 Q3/23 Q4/23 Q1/24 Q2/24 Q3/24 Q4/24 Q2/25 0 2K 4K 6K 8K

Surprise distribution (Last 4 Quarters)

EPS beat statistics

EPS beat (4)
3
Average EPS beat (4)
2.55%
Max EPS beat (4)
6.63%
Min EPS beat (4)
-3.46%

Revenue beat statistics

Revenue beat (4)
N/A
Average Revenue beat (4)
N/A
Max Revenue beat (4)
N/A
Min Revenue beat (4)
N/A

Analysis

In the last 4 quarters, FULC has beaten EPS estimates in 3 out of 4 releases
In the last 4 quarters, FULC has beaten the EPS estimates by 2.5% on average.

FULCRUM THERAPEUTICS INC / FULC Earnings FAQ

What is the most recent earnings date for FULC stock?

FULCRUM THERAPEUTICS INC (FULC) last reported earnings on 2/24/2026.

Did FULCRUM THERAPEUTICS INC (FULC) beat earnings estimates last quarter?

FULCRUM THERAPEUTICS INC (FULC) beat EPS estimates and missed revenue estimates in the most recent quarter.

Can you provide information on how often FULCRUM THERAPEUTICS INC beats earnings estimates?

In the last 4 quarters, FULCRUM THERAPEUTICS INC (FULC) has beaten EPS estimates in 3 out of 4 releases.